BRPI0922022A2 - Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos - Google Patents

Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos

Info

Publication number
BRPI0922022A2
BRPI0922022A2 BRPI0922022A BRPI0922022A BRPI0922022A2 BR PI0922022 A2 BRPI0922022 A2 BR PI0922022A2 BR PI0922022 A BRPI0922022 A BR PI0922022A BR PI0922022 A BRPI0922022 A BR PI0922022A BR PI0922022 A2 BRPI0922022 A2 BR PI0922022A2
Authority
BR
Brazil
Prior art keywords
kits
prevention
individual
treatment
methods
Prior art date
Application number
BRPI0922022A
Other languages
English (en)
Inventor
Yang Yoon-Sun
Il Oh Won
Wook Chang Jong
Yeon Kim Ju
Original Assignee
Medipost Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd
Publication of BRPI0922022A2 publication Critical patent/BRPI0922022A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS, KITS, MÉTODOS DE PREVENÇÃO OU TRATAMENTO DE DOENÇAS NEURAIS DO INDIVÍDUO E RESPECTIVOS USOS. São proporcionados uma composição farmacêutica para prevenção e tratamento de uma doença neural incluindo pelo menos um selecionado a partir do grupo que consiste em células-tronco mesenquimais (MSCs), uma solução de cultura das MSCs, activina A, PF4, decorina, galectina 3, GDF15, glipican 3, MFRP, ICAMS, IGEBPY7, PDGF-AA, SPARCL1, trombospondina-1, WISP1, progranulina, IL-4, um fator induzindo a expressão do mesmo e qualquer combinação dos mesmos e um método para isso.
BRPI0922022A 2008-11-14 2009-11-16 Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos BRPI0922022A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19329308P 2008-11-14 2008-11-14
KR20080113465 2008-11-14
KR1020090072114A KR20100054711A (ko) 2008-11-14 2009-08-05 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
PCT/KR2009/006712 WO2010056075A2 (en) 2008-11-14 2009-11-16 Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases

Publications (1)

Publication Number Publication Date
BRPI0922022A2 true BRPI0922022A2 (pt) 2017-07-11

Family

ID=42279397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922022A BRPI0922022A2 (pt) 2008-11-14 2009-11-16 Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos

Country Status (11)

Country Link
US (1) US10238692B2 (pt)
EP (1) EP2365816B1 (pt)
JP (2) JP5650122B2 (pt)
KR (4) KR20100054711A (pt)
CN (2) CN107412263A (pt)
AU (1) AU2009314797B2 (pt)
BR (1) BRPI0922022A2 (pt)
CA (1) CA2743620C (pt)
MX (1) MX2011005118A (pt)
MY (1) MY179052A (pt)
WO (1) WO2010056075A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2099901B1 (en) 2006-11-30 2015-09-09 Medipost, Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
WO2012060517A1 (ko) * 2010-11-05 2012-05-10 하이스템(주) Ｃｄ45가 발현되는 중간엽 줄기세포를 유효성분으로 포함하는 신경질환 예방 및 치료용 의약 조성
EP2640407A4 (en) * 2010-11-16 2014-07-09 Denis G Kay PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
CA2825641C (en) * 2011-02-02 2016-10-11 Medipost Co., Ltd. Use of icam-1 for prevention or treatment of neurological diseases
WO2012164137A1 (es) 2011-05-30 2012-12-06 Fundación Investigación En Regeneración Del Sistema Nervioso Células madre y células de la estirpe neural derivadas de la glía envolvente olfatoria, y sus aplicaciones
US9950016B2 (en) * 2011-06-24 2018-04-24 National University Of Ireland, Galway Cell secreted proteins for the treatment of myocardial infarction
WO2013039000A1 (ja) * 2011-09-13 2013-03-21 Ochiya Takahiro アルツハイマー病の予防または治療のための医薬品
CN103087983A (zh) * 2011-10-27 2013-05-08 北京清美联创干细胞科技有限公司 一种药物诱导肌肉间充质干细胞增殖和分化的方法及应用
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
KR20130104924A (ko) * 2012-03-16 2013-09-25 (주)히스토스템 항바이러스 작용을 갖는 제대혈 다분화능 줄기세포 유래의 세포활성화 물질을 포함하는 조성물 및 이의 제조방법
EP2659897A1 (en) * 2012-05-02 2013-11-06 Philipps-Universität Marburg Stem cell derived composition for the treatment of acute injury and degenerative diseases
EP2959909B1 (en) 2013-02-20 2019-12-18 Samsung Life Public Welfare Foundation Composition for treating inflammatory brain diseases which includes stem cell as active ingredient
CA2899246C (en) 2013-03-13 2022-12-06 Allosource Fascia fibrous compositions and methods for their use and manufacture
WO2014150784A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2014141219A1 (en) * 2013-03-15 2014-09-18 Blue Horizon International Llc Umbilical cord blood derived stem cell transplantation for the treatment of neural disorder
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
KR101455933B1 (ko) * 2013-05-28 2014-10-31 가톨릭대학교 산학협력단 인간골수유래 중간엽줄기세포와 미노사이클린 병용투여를 통한 다발성경화증 치료제 및 치료방법
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
KR101832203B1 (ko) 2013-12-06 2018-02-27 알로소스 조직의 시트를 건조하는 방법
US20160143950A1 (en) * 2013-12-22 2016-05-26 Nikolai Tankovich Stem cells and stem cell factors for inhibiting the progression of alzheimer's disease
CN103751228B (zh) * 2014-01-27 2016-04-20 贵州神奇药物研究院 治疗老年痴呆的药物及其制备方法
DK3212226T3 (da) 2014-10-31 2020-06-15 Ngm Biopharmaceuticals Inc Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
CN104758923A (zh) * 2015-03-11 2015-07-08 黑龙江天晴干细胞股份有限公司 一种治疗神经损伤的干细胞制剂及其制备方法
US11628190B2 (en) * 2015-08-28 2023-04-18 University Of South Florida Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
US11707488B2 (en) 2015-08-28 2023-07-25 Rohto Pharmaceutical Co., Ltd. ROR1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells
JP7108537B2 (ja) * 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
US11666601B2 (en) 2016-04-28 2023-06-06 Sapporo Medical University Synapse formation agent
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
JP7014449B2 (ja) * 2016-08-14 2022-02-01 ラモット アット テル アビブ ユニバーシティ， リミテッド 神経障害を処置するための間葉系細胞由来エキソソーム
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
US20200108099A1 (en) 2017-02-15 2020-04-09 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis
JPWO2018159432A1 (ja) 2017-03-03 2019-12-26 ロート製薬株式会社 間葉系幹細胞及び医薬組成物
JP7606814B2 (ja) 2017-03-03 2024-12-26 ロート製薬株式会社 間葉系幹細胞及び肝疾患治療剤
WO2018164228A1 (ja) 2017-03-08 2018-09-13 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞を含有する、線維症を伴う疾患の予防又は処置のための医薬組成物、及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる線維症を伴う疾患の予防又は処置方法
EP3636271B1 (en) 2017-06-09 2025-11-19 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for dilated cardiomyopathy
CN107320495A (zh) * 2017-06-19 2017-11-07 北正赛欧（北京）生物科技有限公司 用于促进细胞损伤修复的组合物及其应用
CN111565732A (zh) 2018-01-12 2020-08-21 国立大学法人大阪大学 复层扁平上皮细胞的正常分化-成熟促进剂、上皮疾病治疗剂以及复层扁平上皮细胞的正常分化-成熟促进方法
KR102053868B1 (ko) 2018-01-31 2020-01-22 가톨릭대학교 산학협력단 하비갑개 유래 중간엽 줄기세포를 유효성분으로 포함하는 퇴행성 신경계질환 예방 또는 치료용 약학적 조성물
GB201803010D0 (en) * 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
WO2019203555A1 (ko) * 2018-04-17 2019-10-24 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
KR20190143833A (ko) 2018-06-21 2019-12-31 재단법인 아산사회복지재단 신경퇴행성 질환 예방 또는 치료용 조성물
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
WO2020181411A1 (zh) * 2019-03-08 2020-09-17 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在预防或治疗情绪疾病上的医药用途
MX2022007486A (es) * 2019-12-23 2022-06-29 Denali Therapeutics Inc Variantes de progranulina.
CN111635886A (zh) * 2020-07-02 2020-09-08 成都恩喜医疗管理有限公司 一种间充质干细胞的制备方法与应用
AU2021337035B2 (en) * 2020-09-03 2025-04-17 Two Cells Co., Ltd. Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases
EP4210719A1 (en) * 2020-09-08 2023-07-19 Longeveron Inc. Treatment of alzheimer's disease with allogeneic mesenchymal stem cells
JP2023550542A (ja) * 2020-10-26 2023-12-01 ハダシット メディカル リサーチ サービシズ アンド ディベロップメント リミテッド 間葉系幹細胞およびそれらの培養
WO2022176735A1 (ja) 2021-02-22 2022-08-25 ロート製薬株式会社 糖尿病の予防及び／又は治療剤
WO2022212897A1 (en) 2021-04-01 2022-10-06 The Regents Of The University Of California Genetic modification of mammalian cells to confer resistance to csf1r antagonists
WO2023054918A1 (ko) * 2021-09-30 2023-04-06 주식회사 디자인셀 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물
KR102919897B1 (ko) * 2021-09-30 2026-01-30 주식회사 디자인셀 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물
WO2023080413A1 (ko) 2021-11-02 2023-05-11 주식회사 디자인셀 줄기세포 배양액 및 이로부터 분리된 엑소좀을 유효성분으로 포함하는 안구 질환의 예방 또는 치료용 약학적 조성물
WO2023140348A1 (ja) 2022-01-24 2023-07-27 国立大学法人広島大学 精子処理用組成物、精子運動性改善剤、精子受精能保持剤、精子運動性改善方法及び精子受精能保持方法
JPWO2023140347A1 (pt) 2022-01-24 2023-07-27
WO2023154953A1 (en) * 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
WO2023212663A2 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Pathology-responsive recombinant cells and uses thereof
CN115192609A (zh) * 2022-05-10 2022-10-18 湖南中南大学湘雅口腔医院 间充质干细胞在制备治疗抑郁症的药物中的应用
JPWO2024043232A1 (pt) 2022-08-25 2024-02-29
EP4613851A1 (en) 2022-11-01 2025-09-10 Hiroshima University Sperm treatment composition, sperm motility improving agent, sperm fertility maintaining agent, sperm motility improving method, and sperm fertility maintaining method
EP4613850A1 (en) 2022-11-01 2025-09-10 Hiroshima University Uterine treatment composition, uterine environment-improving agent, implantation aid, embryo transplantation liquid, sperm transplantation liquid, and implantation rate-improving agent
CN116115738B (zh) * 2023-02-22 2024-09-03 重庆大学 细胞因子Igfbp7在制备治疗小鼠老年性肌肉萎缩的药物中的应用
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法
CN117547597A (zh) * 2023-11-28 2024-02-13 四川大学华西医院 基因Wisp1在制备调控MSCs抗衰老表型药物中的应用
CN117384857B (zh) * 2023-12-08 2024-03-19 上海兴瑞一达生物科技有限公司 一种pf4基因修饰的间充质干细胞外泌体及其应用
CN119733100B (zh) * 2025-03-05 2025-05-30 首都医科大学 一种梅克尔软骨细胞分泌蛋白组合及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013A (en) * 1851-04-01 Improvement in wheat-fans
US7354588B1 (en) 1987-05-04 2008-04-08 Dana Farber Cancer Institute Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US20030060398A1 (en) * 1997-09-19 2003-03-27 Gluckman Peter David Neuronal rescue agent
US5837576A (en) 1997-10-31 1998-11-17 Vanguard International Semiconductor Corporation Method for forming a capacitor using a silicon oxynitride etching stop layer
US6900299B1 (en) 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
DE60043624D1 (de) 1999-03-12 2010-02-11 Univ R DNA-Impfung zur Behandlung von Autoimmunerkrankungen
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
PT1179067E (pt) * 1999-05-17 2007-01-31 Biopharm G Biotechnolo Entwi V Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta
US20040208858A1 (en) 2000-04-12 2004-10-21 Gihan Tennekoon Therapeutic uses for mesenchymal stromal cells
CN1449439A (zh) 2000-06-26 2003-10-15 株式会社雷诺再生医学研究所 细胞级分包括能分化为神经细胞的细胞
US20040037775A1 (en) 2000-08-01 2004-02-26 Siahaan Teruna J. Leukocyte internalized peptide-drug conjugates
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
KR100449141B1 (ko) * 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
JP2005517441A (ja) 2002-02-19 2005-06-16 メディポスト・カンパニー・リミテッド 臍帯血由来の間葉幹細胞・前駆細胞の分離培養方法及び間葉組織への分化誘導方法
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
KR100519227B1 (ko) 2002-08-17 2005-10-07 서해영 간엽 줄기세포를 신경세포로 분화시키는 방법
US20040203142A1 (en) 2003-04-14 2004-10-14 Reliance Life Sciences Pvt. Ltd. Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
WO2005026343A1 (ja) 2003-09-09 2005-03-24 Keio University 神経幹細胞の生存及び／又は増殖及び神経突起伸張を促進する方法並びに促進剤、神経幹細胞を含む医薬組成物、検定方法、スクリーニング方法
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
JP4027359B2 (ja) 2003-12-25 2007-12-26 キヤノン株式会社 マイクロ揺動体、光偏向器、画像形成装置
JP2007530543A (ja) * 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞及びその使用法
US7943660B2 (en) 2005-04-15 2011-05-17 Dominion Pharmakine S.L. Inhibitors of the LFA-1/ICAM-1 interaction and uses thereof
EP1767617A1 (en) 2005-09-26 2007-03-28 Letizia Mazzini Mesenchymal stem cells isolation and expansion method and uses thereof
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
KR100792184B1 (ko) 2006-05-12 2008-01-07 재단법인서울대학교산학협력재단 개의 제대혈, 태반 및 개 태아의 심장 유래 다분화능 성체줄기세포, 그 제조방법 및 이를 함유하는 세포 치료제
KR20080049562A (ko) * 2006-11-30 2008-06-04 가톨릭대학교 산학협력단 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
EP2365816A2 (en) 2011-09-21
KR101533989B1 (ko) 2015-07-06
AU2009314797A1 (en) 2010-05-20
CA2743620C (en) 2017-08-15
JP5893084B2 (ja) 2016-03-23
JP2014240388A (ja) 2014-12-25
KR20110087263A (ko) 2011-08-02
JP2012508733A (ja) 2012-04-12
WO2010056075A3 (en) 2010-09-30
JP5650122B2 (ja) 2015-01-07
MX2011005118A (es) 2011-09-26
CA2743620A1 (en) 2010-05-20
KR20100054759A (ko) 2010-05-25
KR20100054731A (ko) 2010-05-25
US10238692B2 (en) 2019-03-26
EP2365816A4 (en) 2013-05-15
MY179052A (en) 2020-10-26
AU2009314797B2 (en) 2012-10-11
KR101114800B1 (ko) 2012-03-13
US20110262393A1 (en) 2011-10-27
CN102281883A (zh) 2011-12-14
WO2010056075A2 (en) 2010-05-20
CN107412263A (zh) 2017-12-01
EP2365816B1 (en) 2017-06-28
KR20100054711A (ko) 2010-05-25

Similar Documents

Publication Publication Date Title
BRPI0922022A2 (pt) Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos
Kim et al. Hesperetin alleviates the inhibitory effects of high glucose on the osteoblastic differentiation of periodontal ligament stem cells
Zhou et al. The effect of quercetin on the osteogenesic differentiation and angiogenic factor expression of bone marrow-derived mesenchymal stem cells
Wu et al. A Bi‐lineage conducive scaffold for osteochondral defect regeneration
Kang et al. Cellular and molecular stimulation of adipose‐derived stem cells under hypoxia
Shi et al. Modulation of chondrocyte motility by tetrahedral DNA nanostructures
Rezai Rad et al. Impact of tissue harvesting sites on the cellular behaviors of adipose‐derived stem cells: Implication for bone tissue engineering
Heo et al. Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells
JP6751465B2 (ja) クロモン誘導体の上皮間葉移行抑制活性を利用した線維症予防及び治療用医薬組成物としての新規用途
BRPI0608109A2 (pt) tratamento de distúrbios ósseos
Xu et al. LncRNA‐TWIST1 promoted osteogenic differentiation both in PPDLSCs and in HPDLSCs by inhibiting TWIST1 expression
Choi et al. Enhanced osteogenesis by collagen‐binding peptide from bone sialoprotein in vitro and in vivo
Peng et al. LncRNA‐AK137033 inhibits the osteogenic potential of adipose‐derived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
Gao et al. A Novel Magnetic Responsive miR‐26a@ SPIONs‐OECs for Spinal Cord Injury: Triggering Neural Regeneration Program and Orienting Axon Guidance in Inhibitory Astrocytic Environment
Liu et al. BMP9 is a potential therapeutic agent for use in oral and maxillofacial bone tissue engineering
Wrona et al. Derivation and characterization of porcine vocal fold extracellular matrix scaffold
Brito et al. MicroRNA-138: an emerging regulator of skeletal development, homeostasis, and disease
Matteini et al. Rejuvenating aged stem cells: therapeutic strategies to extend health and lifespan
Jiang et al. Long non-coding RNAs in bone formation: Key regulators and therapeutic prospects
Paulose et al. Spinal cord regeneration by modulating bone marrow with neurotransmitters and Citicholine: Analysis at micromolecular level
CN102382800A (zh) 一种细胞信号通路抑制剂诱导猪脂肪细胞形成的方法
Zhang et al. Synergistic effects of BMP9 and miR‐548d‐5p on promoting osteogenic differentiation of mesenchymal stem cells
WO2009004632A3 (en) Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
Vu et al. Investigating the effects of conditioned media from stem cells of human exfoliated deciduous teeth on dental pulp stem cells. Biomedicines 2022; 10 (4): 906

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]